CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Stemline Therapeutics Inc  (STML)
Other Ticker:  
 

Stemline Therapeutics Inc's Working Capital Ratio

STML's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




STML Working Capital Ratio (Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
(Jun 30 2018)
II. Quarter
(Mar 31 2018)
I. Quarter
Y / Y Current Liabilities Change 35.01 % 6.96 % 19.84 % 31.61 % 48.32 %
Y / Y Current Assets Change 33.13 % 20.83 % 21.79 % 52.37 % 11.57 %
Working Capital Ratio MRQ 5.07 2.97 4.65 5.38 5.14
Overall Ranking # # # # #
Seq. Current Liabilities Change 24.62 % 22.4 % -5.2 % -6.64 % -1.28 %
Seq. Current Assets Change 112.41 % -21.7 % -18.13 % -2.23 % 92.77 %



Working Capital Ratio first quarter 2019 Comment
Stemline Therapeutics Inc's Current Assets grew by 112.41 % in I. Quarter sequntially, faster than Current Liabilities, this led to improvement in Stemline Therapeutics Inc's Working Capital Ratio to 5.07, Working Capital Ratio remained below Stemline Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 130 other companies have achieved higher Working Capital Ratio than Stemline Therapeutics Inc in first quarter 2019. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is STML most successful ?
Working Capital Ratio STML on the trailing twelve month basis
Working Capital Ratio first quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 131
Healthcare Sector # 279
Overall Market # 747


Working Capital Ratio Statistics
High Average Low
31.09 8.78 2.63
(Sep 30 2013)   (Dec 31 2017)




Financial Statements
Stemline Therapeutics Inc's Current Liabilities $ 26 Millions Visit STML's Balance sheet
Stemline Therapeutics Inc's Current Assets $ 134 Millions Visit STML's Balance sheet
Source of STML's Sales Visit STML's Sales by Geography




Companies with similar Working Capital Ratio in the quarter endingMar 31 2019, within Major Pharmaceutical Preparations Industry Working Capital RatioMar 31 2019 MRQ Current AssetsMar 31 2019 MRQ Current Liabilities
Newlink Genetics Corp  13.33 $ 118.277  Millions$ 8.872  Millions
Sierra Oncology, Inc.  13.07 $ 94.607  Millions$ 7.238  Millions
Ultragenyx Pharmaceutical Inc.  12.77 $ 786.887  Millions$ 61.621  Millions
Arbutus Biopharma Corp  12.75 $ 112.486  Millions$ 8.823  Millions
Menlo Therapeutics Inc.  12.59 $ 125.222  Millions$ 9.943  Millions
Sarepta Therapeutics, Inc.  12.53 $ 1,671.423  Millions$ 133.381  Millions
Mirati Therapeutics, Inc.  12.52 $ 306.382  Millions$ 24.465  Millions
Corvus Pharmaceuticals, Inc.  12.39 $ 107.004  Millions$ 8.635  Millions
Oramed Pharmaceuticals Inc.  12.33 $ 29.601  Millions$ 2.401  Millions
Catabasis Pharmaceuticals Inc  12.25 $ 52.649  Millions$ 4.298  Millions
Spring Bank Pharmaceuticals, Inc.  12.11 $ 47.825  Millions$ 3.948  Millions
Savara Inc.  12.05 $ 107.518  Millions$ 8.920  Millions
Iveric Bio, Inc.  12.05 $ 119.034  Millions$ 9.882  Millions
Kala Pharmaceuticals, Inc.  11.59 $ 150.449  Millions$ 12.982  Millions
Synlogic, Inc.  11.53 $ 113.792  Millions$ 9.867  Millions
Xeris Pharmaceuticals Inc  11.45 $ 153.445  Millions$ 13.406  Millions
Vanda Pharmaceuticals Inc.  11.18 $ 306.498  Millions$ 27.423  Millions
Aeglea Biotherapeutics, Inc.  10.74 $ 126.818  Millions$ 11.806  Millions
Reata Pharmaceuticals Inc  10.63 $ 317.472  Millions$ 29.870  Millions
Intra-cellular Therapies, Inc.  10.49 $ 321.128  Millions$ 30.626  Millions
Five Prime Therapeutics Inc  10.41 $ 250.541  Millions$ 24.072  Millions
Siga Technologies Inc  10.20 $ 123.539  Millions$ 12.107  Millions
Rocket Pharmaceuticals, Inc.  10.14 $ 199.619  Millions$ 19.680  Millions
Agile Therapeutics Inc  10.09 $ 11.938  Millions$ 1.183  Millions
United Therapeutics Corp  10.09 $ 1,942.500  Millions$ 192.500  Millions
Ocular Therapeutix, Inc.  9.97 $ 79.172  Millions$ 7.939  Millions
Zynerba Pharmaceuticals, Inc.  9.94 $ 74.219  Millions$ 7.466  Millions
Biohaven Pharmaceutical Holding Co Ltd.  9.60 $ 227.373  Millions$ 23.693  Millions
Tonix Pharmaceuticals Holding Corp.  9.54 $ 19.182  Millions$ 2.011  Millions
Uniqure N.v.  9.51 $ 213.195  Millions$ 22.418  Millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BOTY's Profile

Stock Price

BOTY's Financials

Business Description

Fundamentals

Charts & Quotes

BOTY's News

Suppliers

BOTY's Competitors

Customers & Markets

Economic Indicators

BOTY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071